Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia (NASDAQ: LQDA) will present data on the investigational use of L606 (liposomal treprostinil) inhalation suspension at the ATS 2024 International Conference. The company aims to demonstrate the safety and tolerability of L606 in patients with PAH and PH-ILD through a Phase 3, 2-part, open-label, multicenter study. The presentation will be on May 22, 2024, in San Diego, California. Liquidia plans to initiate a global pivotal efficacy trial later this year based on the study's positive results.
Liquidia (NASDAQ: LQDA) will be presenting at the BofA Securities Health Care Conference 2024, where Michael Kaseta, the COO and CFO, will update investors on the company's business. The presentation will take place on May 14, 2024, at 5:00 p.m. PT in Las Vegas, Nevada. A webcast of the event will be accessible on Liquidia's website, with a recorded version available for 30 days post-event.
Liquidia (NASDAQ: LQDA) will report its first quarter 2024 financial results on May 14, 2024. A live webcast will be hosted at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website. A rebroadcast will be archived for one year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.